NASDAQ: KLRA Kailera Therapeutics, Inc. 10-Q

Kailera debuts Q1 2026: $79M loss, $582M cash, IPO adds $719M runway into mid-2028

Filed May 26, 2026 · Period ending March 31, 2026 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade KLRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · May 28, 2026 11:05 PM